• Complex or advanced cancer: Supporting treatment decisions in metastatic or treatment-resistant disease.
• Relapsed malignancy: Exploring broader therapeutic options following failure of previous therapies.
• Treatment comparison: Assessing tumour response across multiple drug classes and natural compounds.
• Prioritising potential therapies: Highlighting agents that show stronger tumour cell response in vitro.
• Integrative oncology strategies: Informing combined conventional and adjunctive therapeutic approaches.

Overview

chemo-scale™ 60 substances evaluates how viable tumour-derived cells respond when exposed to a wide panel of chemotherapeutic drugs, repurposed medications and selected natural agents. This broader testing approach allows comparison of potential treatment options based on observed tumour cell sensitivity.

Assessing response at the cellular level may help highlight therapies with a higher likelihood of effectiveness and identify options that appear less suitable. This information can be particularly relevant where treatment choices are complex or previous therapies have not achieved the desired outcome.

Results are considered alongside tumour type, stage, prior treatment history and overall oncology care planning. Reviewing chemosensitivity findings in this wider clinical context can support more individualised discussion around treatment selection and ongoing management.